XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.3
SEGMENT REPORTING (Tables)
 9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment The following table presents a summary of the revenues and adjusted EBITDA of our three operating segments for the three and nine months ended September 30, 2023 and 2022:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2023202220232022
Revenues by segment:
RCM$46,582 $46,875 $142,973 $134,200 
EHR
Recurring revenue
Acute EHR27,925 27,237 83,886 81,333 
Post-acute EHR3,594 3,817 11,230 11,504 
Total recurring EHR revenue31,519 31,054 95,116 92,837 
Non-recurring revenue
Acute EHR2,624 3,500 8,460 9,467 
Post-acute EHR350 395 1,075 1,551 
Total non-recurring EHR revenue2,974 3,895 9,535 11,018 
Total EHR revenue$34,493 $34,949 $104,651 $103,855 
Patient Engagement1,637 1,003 5,943 5,369 
Total revenues$82,712 $82,827 $253,567 $243,424 
Adjusted EBITDA by segment:
RCM$4,623 $8,750 $18,205 26,395 
EHR5,669 5,751 17,394 17,621 
Patient Engagement(570)(1,152)(6)(1,345)
Total adjusted EBITDA$9,722 $13,349 $35,593 $42,671 
Schedule of Reconciliation Of Net Income From Continuing Operations To Adjusted Income (Loss) From Before Interest, Taxes, Depreciation And Amortization The following table reconciles net income to adjusted EBITDA:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2023202220232022
Net income (loss), as reported$(3,562)$2,161 (3,315)13,350 
Deferred revenue and other purchase accounting adjustments— — — 109 
Depreciation expense297 622 1,392 1,890 
Amortization of software development costs2,194 1,024 5,506 2,283 
Amortization of acquisition-related intangibles4,014 4,486 12,043 12,917 
Stock-based compensation1,038 1,864 2,162 5,284 
Severance and other non-recurring charges7,392 410 15,313 1,671 
Interest expense and other, net2,847 1,416 7,836 3,255 
(Gain) loss on contingent consideration— 589 — (992)
Provision (benefit) for income taxes(4,498)777 (5,344)2,904 
Total adjusted EBITDA$9,722 $13,349 $35,593 $42,671